Can India repeat the success of generics in US (United States) biosimilar market? an analysis of current FDA's stand on biosimilars

S. Moorkoth, Y. Gujar, D. Bukka

Research output: Contribution to journalArticle

Original languageUndefined/Unknown
Pages (from-to)27-31
Number of pages5
JournalPharma Times
Volume45
Issue number1
Publication statusPublished - 2013

Cite this

@article{ce5fc66ff1d44b2dbbb237fdb16413bc,
title = "Can India repeat the success of generics in US (United States) biosimilar market? an analysis of current FDA's stand on biosimilars",
author = "S. Moorkoth and Y. Gujar and D. Bukka",
note = "cited By 0",
year = "2013",
language = "Undefined/Unknown",
volume = "45",
pages = "27--31",
journal = "Pharma Times",
issn = "0031-6849",
publisher = "Indian Pharmaceutical Association",
number = "1",

}

Can India repeat the success of generics in US (United States) biosimilar market? an analysis of current FDA's stand on biosimilars. / Moorkoth, S.; Gujar, Y.; Bukka, D.

In: Pharma Times, Vol. 45, No. 1, 2013, p. 27-31.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Can India repeat the success of generics in US (United States) biosimilar market? an analysis of current FDA's stand on biosimilars

AU - Moorkoth, S.

AU - Gujar, Y.

AU - Bukka, D.

N1 - cited By 0

PY - 2013

Y1 - 2013

M3 - Article

VL - 45

SP - 27

EP - 31

JO - Pharma Times

JF - Pharma Times

SN - 0031-6849

IS - 1

ER -